Non-peptide NK1 receptors antagonists

A compound of Formula I

• and the pharmaceutically acceptable salt thereof, wherein
• ▪, [Circlesolid], ▴, indicate all stereoisomers,
• R is:
• furyl
• benzofuryl, or
• benzoxazolyl, wherein each of the foregoing is unsubstitute, mono-, di- or trisubstituted by
• alkyl,
• hydroxy,
• alkoxy,
• halogen,
• —CF3,
• carboxy,
• sulfonamide, or
• nitro;
• R1 and R2 are each independently H or C1-C4 alkyl;
• m is an integer from 0 to 3;
• X is NR8 where R8 is H or C1-C4alkyl;
• R3 is hydrogen or C1-C4 alkyl;
• n is an integer from 1 to 2;
• R4 is indolyl, wherein said groups are substituted, mono, di- or trisubstituted by alkyl, hydroxy or formyl;
• R9 is hydrogen or C1-C4 alkyl;
• R5 and R7 are each independently hydrogen or (CH2)pR10 where:
• p is an integer of 1 to 3, and
• R10 is H, CH3, CN, OH, OCH3, CO2CH3, NH2, NHCH3, or N(CH3)2;
• q is integer of 0 to 4;
• R6 is phenyl,
• wherein the foregoing is unsubstituted, mono-, di- or trisubstituted by
• alkyl,
• hydroxy,
• alkoxy,
• halogen,
• CF3,
• NO2,
• N(CH3)2,
• OCF3,
• SONH2,
• NH2,
• CONH2,
• CO2CH3, or
• CO2H, and
• R5 and R6 when joined by a bond, can form a ring.